Memphasys Targets Fast-Track FDA Pathway for Felix to Tap US IVF Market
Get your Free Report on Top 5 ASX stocks for 2025
Reproductive biotechnology developer Memphasys Limited (ASX: MEM) announced a board level reassessment on 25 September 2026 that identified a potentially faster, cost effective regulatory pathway for its Felix Sperm Separation System in the United States.
The company identified a legally marketed predicate device working alongside specialist regulatory advisers, enabling Felix to pursue the US FDAβs established 510(k) clearance route based on substantial equivalence. This streamlined approach replaces the more complex De Novo pathway previously contemplated.
Memphasys will now initiate a Pre-Submission (Q-Submission) engagement with the agency for formal feedback, targeting a full 510(k) filing in Q1 CY2027 to access an American IVF sector valued at roughly US$5.9 billion, representing approximately 20% of the global market.
Company leadership emphasized that the strategic pivot unlocks access to around 500 US fertility clinics without diluting focus or draining operational resources. The US regulatory initiative will be strictly ringfenced to preserve cash flow and run in parallel with the group's ongoing commercialization push.
This filing timeline integrates directly into existing revenue activities across Europe, Australia, New Zealand and MENA where Memphasys continues to report repeat cartridge orders and clinician uptake across Italy and the UK.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether itβs appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
Mesoblast Secures FDA Clearance for New Ryoncil Co..
BCAL Diagnostics (ASX:BDX) Launches Avantect Multi..
Genetic Signatures and Microba Agree to Commercial..
KTEK Aerosystems (ASX: KTK) Locks In Initial Defen..
Sultan Resources Secures Large-Scale Copper-Gold G..